Neratinib (Nerylnx) has been approved by the TGA as extended adjuvant treatment to prevent relapse in women with HER2+ breast cancer. The tyrosine kinase inhibitor is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy. The sponsor, Specialised Therapeutics, says it is currently applying ...
Neratinib approved as adjuvant therapy in early HER2 breast cancer
By Michael Woodhead
19 Mar 2019